Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.79 |
| ▸ | MMP2 | P08253 | 3/20 | 0.79 |
| ▸ | MMP9 | P14780 | 3/20 | 0.79 |
| ▸ | APP | P05067 | 3/20 | 0.74 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 3/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.63 |
| ▸ | ARG1 | P05089 | 1/20 | 0.63 |
| ▸ | TYR | P14679 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142977 | 1.00 | MMP1 (0.79) | MMP1MMP2MMP9APPMAOA | |
| SCHEMBL28003961 | 0.95 | MMP1 (0.86) | MMP1MMP2MMP9APPMAOA | |
| SCHEMBL28003962 | 0.95 | MMP1 (0.86) | MMP1MMP2MMP9APPMAOA | |
| SCHEMBL16382856 | 0.89 | MMP1 (0.76) | MMP1MMP2MMP9APPMAOA | |
| SCHEMBL28052301 | 0.89 | MMP1 (0.76) | MMP1MMP2MMP9APPMAOA | |
| SCHEMBL16382866 | 0.88 | MMP1 (1.00) | MMP1MMP2MMP9APPMAOA | |
| SCHEMBL8847896 | 0.88 | MMP1 (1.00) | MMP1MMP2MMP9APPMAOA | |
| SCHEMBL107880 | 0.87 | ERCC1 (0.60) | MMP1MMP2MMP9APPACHE | |
| SCHEMBL108637 | 0.87 | ERCC1 (0.60) | MMP1MMP2MMP9APPACHE | |
| SCHEMBL141914 | 0.87 | ERCC1 (0.60) | MMP1MMP2MMP9APPACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | claimed |
| US-8227643-B2 | Sirtuin 1 and the treatment of neurodegenerative diseases | PROTEOTECH, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | PROTAMED, INC. | 2012-03-08 | — | — | US | claimed |
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PROTAMED, INC. | 2011-06-16 | — | — | US | claimed |
| US-20110015272-A1 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases | PROTEOTECH INC. | 2011-01-20 | — | — | US | claimed |
| US-7714170-B2 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH, INC. (US) | 2010-05-11 | — | — | US | claimed |
| US-7601876-B2 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTEOTECH, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTAMED, INC. | 2009-06-04 | — | — | US | claimed |
| WO-2009017848-A9 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC (US) | 2009-04-30 | — | — | WO | claimed |
| WO-2009017848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | claimed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | claimed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | claimed |
| EP-1751097-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | Proteotech, Inc. (US) | 2007-02-14 | — | — | EP | claimed |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTAMED, INC. | 2006-09-07 | — | — | US | claimed |
| WO-2005113489-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| EP-1511710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER S DISEASE, TYPE 2 DIABETES, AND PARKINSON S DISEASE | Proteotech, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTAMED, INC. | 2004-07-01 | — | — | US | claimed |
| WO-2003101927-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTEOTECH, INC. (US) | 2003-12-11 | — | — | WO | claimed |
| EP-0900781-B1 | Phenolic acid amides of hydroxy substituted benzylamines | HAARMANN & REIMER GMBH (DE) | 2002-03-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | IAPP, SNCA, IDE | MMP1 2158/4885MMP2 1770/4885MMP9 4373/4885 |
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PSEN2, PSEN1, MAPT | MMP1 3421/4885MMP2 3867/4885MMP9 3941/4885 |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | IAPP, SNCA, BACE2 | MMP1 3402/4885MMP2 3593/4885MMP9 4680/4885 |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | NR1H2, NR1H3, MSR1 | MMP1 1583/4885MMP2 3437/4885MMP9 3479/4885 |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | NR1H2, NR1H3, NR1H4 | MMP1 2448/4885MMP2 3979/4885MMP9 3291/4885 |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | IAPP, SNCA, APP | MMP1 2156/4885MMP2 1752/4885MMP9 4401/4885 |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | MMP1 4760/4885MMP2 4375/4885MMP9 4665/4885 |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | APP, BACE1, BACE2 | MMP1 1903/4885MMP2 827/4885MMP9 1537/4885 |
| US-20110015272-A1 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases | SIRT1, SIRT3, SIRT2 | MMP1 2897/4885MMP2 3097/4885MMP9 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.